Better Evidence Starts With the Right Claims Data Source
ISPOR 2026 research from Magnolia Market Access highlights why the right claims data source depends on the evidence question, outcome, and decision it needs to support.
Designing Evidence That Supports Access Decisions
Real-world evidence can help reduce uncertainty in access decisions by addressing questions clinical trials may not fully answer, including long-term outcomes, real-world utilization, and system-level impact.
Access Is a Design Decision: Why Commercial Performance Is Now Determined by Access, Not Approval
Access is now shaping commercial performance. Learn how policy, payer dynamics, and evidence are redefining access strategy and what it requires from organizations today.
Where Ecosystem Mapping Becomes Strategy
Market access ecosystem mapping helps biopharma teams move from identifying stakeholders to understanding how influence operates across the access landscape, enabling more coordinated engagement, stronger alignment, and more informed decision-making.
Designing for Coverage, Not Just Approval
Regulatory approval does not guarantee payer coverage. As reimbursement decisions increasingly depend on comparative value, budget impact, and real-world evidence, integrating HEOR and payer considerations into clinical trial design can help biopharma teams anticipate access challenges and support stronger reimbursement discussions at launch.
Case Study: Digital Phenotyping — Harnessing AI & Unstructured Data to Revolutionize Life-Saving Diagnostics
How AI-driven EMR analysis helped identify high-risk cardiovascular patients and support earlier intervention.
Case Study: Linking Real-World Datasets to Identify Cost Drivers in Lung Transplantation
How a biotechnology company used real-world data analysis to uncover cost drivers and validate the economic impact of EVLP.
Why Real-World Evidence Is Reshaping the Economics of Drug Pricing
Real-world evidence is no longer just a regulatory checkbox—it’s a strategic driver of pricing, access, and payer engagement. Discover how leading life sciences teams are embedding RWE earlier to shape reimbursement strategy, optimize launch planning, and unlock value-based contracts.
Deal-Driven Policy, Direct-to-Patient Models, and State Momentum: Preparing for 2026
As policy dynamics accelerate across federal and state channels, manufacturers must prepare for multiple scenarios and align internal planning. Key readiness priorities for 2026.
Payer Research: A Strategic Driver of ROI Across the Lifecycle
Design research payers can use: focus on real-world outcomes, durability, and total cost of care; bring payer input in early and often; and pressure-test access levers pre-launch. Turn strong science into coverage, reimbursement, and measurable ROI.